Minocycline in Clinically Isolated Syndrome of MS
A fter a first focal clinical demyelinating event (also called a clinically isolated syndrome), the risk of conversion to multiple sclerosis is high. Minocycline is a tetracycline antibiotic agent that has immunemodulating properties; preliminary data have shown activity of minocycline in patients with multiple sclerosis. [1] [2] [3] [4] Minocycline has a good safety profile, 5 although rash, headache, dizziness, and photosensitivity are common side effects. Pseudotumor cerebri and hypersensitivity syndromes are rare but serious complications, and hyperpigmentation may occur with long-term use. Antibiotic resistance is infrequently associated with minocycline therapy. 6 In one small clinical trial involving patients with relapsingremitting multiple sclerosis, minocycline therapy reduced the mean number of lesions detected with the use of gadolinium enhancement ("enhancing lesions") on magnetic resonance imaging (MRI) by 84% from the number seen during a run-in period (P = 0.03), 7 and in another small trial, 8 the total number of enhancing lesions was 63% lower with the combined use of glatiramer acetate plus minocycline than with glatiramer acetate plus placebo, although the difference was not significant (P = 0.08). Given these findings, we performed a multicenter, randomized, double-blind, placebo-controlled trial to determine whether minocycline reduces the risk of conversion from a first clinical demyelinating event to multiple sclerosis diagnosed on the basis of the 2005 McDonald criteria. 9 
Me thods

Trial Oversight
This trial was conducted at 12 Canadian multiple sclerosis clinics; Health Canada and the institutional review board at each participating site provided regulatory oversight. The trial was monitored by an independent data and safety monitoring committee. The trial was sponsored by the Multiple Sclerosis Society of Canada; the sponsor had no role in the review of the final statistical analysis plan or drafts of the manuscript, in the interpretation of the trial results, or in the decision to submit the manuscript for publication. The study drug and placebo were purchased from Apotex. The authors vouch for the completeness and accuracy of the data and for the fidelity of the trial to the protocol, available with the full text of this article at NEJM.org.
Trial amendments are described in Table S2 in the Supplementary Appendix, available at NEJM.org.
Participants
Participants were eligible for inclusion in the trial if they were between 18 and 60 years of age; provided written informed consent; had had a single clinically isolated demyelinating event such as optic neuritis or a brainstem, cerebral, cerebellar, or myelopathy syndrome within the previous 180 days; and had at least two lesions larger than 3 mm in diameter on T 2 -weighted MRI of the brain (one lesion had to be ovoid, periventricular, or infratentorial -typical of demyelinating disease). Key exclusion criteria were an alternative explanation for the event, a previous event reasonably attributable to demyelination, or a diagnosis of multiple sclerosis according to the 2005 McDonald criteria. 9 Inclusion and exclusion criteria are described in Table S1 in the Supplementary Appendix. Before the trial began in 2008, the 2005 McDonald criteria were used to diagnose a clinically isolated syndrome. A diagnosis of relapsing-remitting multiple sclerosis requires evidence that inflammatory demyelination has affected at least two regions of the central nervous system (i.e., dissemination in space) and that episodes of inflammation have occurred at least twice (i.e., dissemination in time). Advances in understanding the predictive clinical significance of demyelinating lesions on MRI led to rapid updates in the diagnostic criteria for multiple sclerosis. With the 2005 McDonald criteria, 9 a second clinical relapse was no longer required because a diagnosis of multiple sclerosis could be confirmed on the basis of the occurrence of a new demyelinating lesion on follow-up MRI (meeting the criterion of dissemination in time) if there were lesions involving several of the brain regions typically involved in multiple sclerosis (meeting the criterion of dissemination in space). With the 2010 McDonald criteria, 10 the presence of both enhancing and nonenhancing lesions on the initial MRI confirmed dissemination in time, because this was now known to indicate that the lesions were of different ages. Furthermore, lesions did not have to be as widespread as required in the 2005 McDonald criteria to confirm dissemination in space, so a diagnosis could be confirmed at the onset of a first demyelinating event when these conditions were met. The 2010 McDonald criteria were published during the time this trial was A Quick Take is available at NEJM.org T h e ne w e ngl a nd jou r na l o f m e dicine ongoing. Participants who had both enhancing and nonenhancing lesions on their baseline MRI could then receive a diagnosis of multiple sclerosis 11 ; however, they were still offered inclusion in this trial, and the study outcome, which they could meet with the occurrence of a clinical relapse or MRI changes, remained conversion to multiple sclerosis according to the 2005 McDonald criteria.
Randomization and Blinding
Participants were randomly assigned to receive either 100 mg of generic minocycline, administered orally in capsule form twice daily, or matching placebo for up to 24 months or until a diagnosis of multiple sclerosis was confirmed on the basis of the 2005 McDonald criteria. The minocycline and placebo capsules were distributed to the trial sites by central trial pharmacists at the University of Calgary. Randomization was performed in a 1:1 ratio in permuted blocks of four that were generated by the trial biostatistician, with stratification according to site and to high risk versus low risk for conversion to multiple sclerosis. To reduce the chance of imbalance between the study groups in the number of highrisk participants, we assigned to the high-risk subgroup participants who had more than one enhancing lesion on the screening MRI 12 or who had sufficient distribution and number of multifocal lesions to meet the 2005 McDonald criterion of dissemination in space of white-matter lesions in the diagnosis of multiple sclerosis. 9 At the baseline visit, the trial nurse, who was unaware of the group assignments, selected the next sequentially numbered bottle of minocycline or placebo (in masked, identical-looking bottles) for the assigned subgroup. Participants started taking the study drug or placebo on the evening of randomization, after which they took it twice daily at 12-hour intervals. Supplements containing iron were avoided within 4 hours before and after intake. 13 The participants and trial-center personnel (except the central trial pharmacists) were unaware of the study-group assignments. If the study drug or placebo was discontinued in a participant, follow-up continued. Concurrent systemic glucocorticoids, tetracycline antibiotics, or approved or experimental disease-modifying therapies for multiple sclerosis were not allowed.
Each participant was assessed by evaluating and treating physicians who were unaware of the study-group assignments. Independent readers at the University of British Columbia MS/MRI Research Group, who were unaware of the studygroup assignments, assessed the MRI scans for acceptable quality and reported the number and anatomical distribution of demyelinating lesions. To minimize variability in interpretation of the images, MRI scans for each participant were evaluated by the same reader, as described previously.
14 Questionnaires on the effectiveness of the blinding of study-group assignments were completed by the participant, trial nurse, and treating physician at the end of the study or the month 24 visit. Standardized imaging reports were reviewed in a blinded manner by a neurologist (a member of the clinical steering committee), who confirmed that the MRI criteria for eligibility had been met, made the appropriate subgroup assignment, and determined whether a participant met the criteria for the primary outcome.
Procedures
Participants underwent routine blood testing, clinical assessments, and Expanded Disability Status Scale (EDSS) assessments (scores range from 0 to 10.0, with half-point increments, with higher scores indicating greater disability) 15 at screening, at baseline, at months 1, 3, 6, 12, 18, and 24, and at the time of an early trial withdrawal. Participants were contacted by telephone at months 9, 15, and 21 for assessment of adverse events and for identification of symptoms that could indicate a relapse. In a blinded manner, the treating physician provided care and identified adverse events and possible relapses, and the evaluating physician, who was also unaware of the study-group assignments, performed the EDSS assessment. Adverse events were identified by patient report and by laboratory testing and physical examination. The adverse events detected on laboratory testing and physical examination were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0.
16 At each visit, the pills were counted to determine adherence and additional pills were dispensed. Clinical data were recorded in a data management system (iDataFax) 17 at the participating sites and were managed at the University of Calgary.
A cranial MRI (proton density, T 2 -weighted; fluid-attenuated inversion recovery; axial three-dimensional T 1 -weighted gradient-echo; and T 1 -weighted images before and after gadolinium enhancement [0.1 mmol per kilogram of body weight]) was obtained in accordance with standardized imaging protocols at screening (baseline), at months 3, 6, 12, and 24, and at the time of an early trial withdrawal. The screening (baseline) MRI was performed within 10 to 18 days before the baseline assessment and at least 7 days after completion of glucocorticoid treatment, if glucocorticoids were used for the initial treatment of the clinically isolated syndrome.
Outcomes
The primary outcome was conversion to multiple sclerosis, diagnosed on the basis of the 2005 McDonald criteria, 9 within 6 months after randomization. Secondary outcomes included conversion to multiple sclerosis within 24 months and MRI outcomes (change in lesion volume on T 2 -weighted images, cumulative number of enhancing lesions on T 1 -weighted MRI, and cumulative combined number of unique lesions [i.e., new enhancing lesions on T 1 -weighted MRI plus new and newly enlarged lesions on T 2 -weighted MRI, without double-counting]) at 6 months and 24 months.
A relapse indicating the diagnosis of multiple sclerosis was confirmed by the treating physician, who was unaware of the study-group assignments, and then confirmed in a blinded manner by a neurologist who was a member of the clinical steering committee. Confirmation of a relapse required clinical stability for the previous 30 days and the appearance of a new, or the reappearance of a previously stable, neurologic abnormality lasting at least 48 hours, in the absence of fever or infection. In a blinded manner, the evaluating physician had to confirm objective evidence of at least one new neurologic abnormality on examination. A minimum increase of 0.5 points in the EDSS score, an increase of 2 points in at least one of eight functional-system subscale scores of the EDSS, or an increase of 1 point on two functional-system subscale scores of the EDSS was also required to confirm a relapse.
Statistical Analysis
Calculations of sample size were based on the assumption that 65% of the participants in the placebo group would have conversion to multiple sclerosis on the basis of 2005 McDonald criteria within 6 months after randomization, and 85% within 24 months after randomization. We estimated that a sample size of 154 participants would provide 80% power to detect an absolute difference of 25 percentage points at both 6 months and 24 months and allow for a withdrawal rate of 10%; a risk difference of 25 percentage points was considered to be clinically meaningful.
The primary analysis in the intention-to-treat population was designed to compare the risk of conversion to multiple sclerosis in the minocycline group with that in the placebo group over time with the use of an actuarial life-table approach. Actuarial life-tables were used because the exact dates on which subclinical disease (as detected on MRI) occurred were unknown, because MRI data were collected on a schedule and MRI was not performed on the basis of clinical change or in direct relation to a specific clinical event. Data for participants who withdrew from the trial were censored during the interval of their last follow-up visit. Post hoc adjusted risk estimates were stratified according to the number of enhancing lesions at baseline, which was not balanced between the study groups at trial entry. Wald tests and log-rank tests were used to assess the significance of the results. Sensitivity analyses were performed to support the findings of the primary analysis. The propensity-score method 18 was used to impute missing data from participants who withdrew from the trial before month 6, with the number of enhancing lesions and dissemination in space at the baseline evaluation as covariates in the logistic-regression model. Multiple imputation generated five complete data sets that were analyzed individually, and the results were combined to produce valid estimates. A prespecified per-protocol analysis was performed on data from only the participants who reported at least an 80% rate of adherence to minocycline or placebo. Both supporting analyses used stratified actuarial lifetables, adjusted for the number of enhancing lesions at baseline. We also performed a prespecified sensitivity analysis in which all participants who withdrew from the study were considered to have treatment failure. Discretetime complementary log-log regression models were used post hoc to identify potential confounding baseline factors and to assess differen-T h e ne w e ngl a nd jou r na l o f m e dicine tial treatment effects by comparing hazard ratios within subgroups with the use of tests for interaction. We compared EDSS scores and relapse outcomes (the number of participants who had a relapse that confirmed the diagnosis of multiple sclerosis) between study groups post hoc in an unadjusted analysis and in an analysis that was adjusted for the number of enhancing lesions at baseline, using an analysis of covariance, Poisson regression models, or log-binomial regression models.
Analyses of MRI outcomes included participants who had at least one follow-up MRI. The change in mean lesion volume on T 2 -weighted MRI from baseline was compared between the two study groups with the use of a linear mixed model, which included a random intercept to account for the within-participant correlation. The mean cumulative number of new enhancing lesions and the mean cumulative combined number of unique lesions were compared with the use of negative binomial regression models. Adjusted analyses included the number of enhancing lesions at baseline as the covariate.
Adverse events were compared between study groups with the use of chi-square tests. The integrity of blinding was assessed by the blinding index described by James et al. 19 Two-sided P values of less than 0.05 were considered to indicate statistical significance. All statistical analyses were performed with the use of SAS software, version 9.3 (SAS Institute), or Stata software, version 14.0 (StataCorp).
R esult s
Trial Population
From December 2008 through June 2013, a total of 236 participants were screened, and 143 underwent randomization from January 2009 through July 2013 (Fig. 1) . One participant underwent randomization in error, having met the multiple sclerosis outcome before the time of randomization. The intention-to-treat analysis included 142 participants: 72 in the minocycline group and 70 in the placebo group. The placebo group included significantly more participants whose symptom onset was in the spinal cord (P = 0.04) and significantly more participants who had more than one enhancing lesion on MRI at baseline (P = 0.04). The characteristics of the participants at baseline were otherwise similar in the two study groups (Table 1, and Table S3 in the Supplementary Appendix) .
Before reaching the outcome of conversion to multiple sclerosis or the month 6 time point, 13 participants (9.2%) withdrew from the trial (9 participants in the minocycline group and 4 in the placebo group), and 9 participants (6.3%) discontinued the study drug or placebo (5 participants in the minocycline group and 4 in the placebo group) but continued clinical follow-up. After reaching month 6, but before reaching the outcome of conversion to multiple sclerosis or the month 24 time point, 13 additional participants (9.2%) withdrew from the trial (9 participants in the minocycline group and 4 in the placebo group, including 2 in the minocycline group and 2 in the placebo group who had previously discontinued the study regimen but had continued follow-up). Six participants (4.2%) who were enrolled in 2013 completed trial participation at month 12 (Table S2 in the Supplementary Appendix) (3 participants in each group). Overall, data for 32 participants (22.5%) were censored in the 24-month intention-to-treat analysis. Over 24 months, trial withdrawals because of adverse effects of the study drug or placebo were more frequent in the minocycline group than in the placebo group (6 participants in the minocycline group vs. 1 in the placebo group), but withdrawals for other reasons were balanced between the study groups. In total, 13 participants (9.2%) discontinued the study drug or placebo but continued follow-up until they reached the study outcome or month 24 (9 participants in the minocycline group and 4 in the placebo group); they were included in the intention-totreat analysis. The mean duration of treatment was similar in the two study groups: 12.7 months in the minocycline group and 11.5 months in the placebo group (P = 0.41 by Student's t-test). Adequate blinding of study-group assignments was confirmed among the participants, nurses, and physicians (Table S4 in * There were no significant between-group differences in characteristics at baseline except for symptom onset in the spinal cord (P = 0.04) and number of lesions enhanced on magnetic resonance imaging (MRI) (P = 0.04). CIS denotes clinically isolated syndrome, and EDSS Expanded Disability Status Scale. † Race and ethnic group were reported by the participant. Nonwhite included South Asian (9 participants), Asian (5 participants), black (3 participants), aboriginal (2 participants), other (2 participants), and unknown (1 participant); multiple ethnic groups could be selected by the participant. ‡ Scores on the EDSS range from 0 to 10.0 on a scale with half-point increments, with higher scores indicating greater disability. § Multiple anatomical locations could be selected. ¶ Data were missing for 6 participants (3 in the minocycline group and 3 in the placebo group). McDonald criteria) within 6 months. The unadjusted risk difference of 27.6 percentage points (P = 0.001) exceeded the prespecified clinically meaningful absolute difference of 25 percentage points (Table 2) . After the number of enhancing lesions at baseline was taken into account, the adjusted risk difference at 6 months was 18.5 percentage points (43.0% with minocycline vs. 61.5% with placebo, P = 0.01). Adjustment for symptom onset in the spinal cord, symptoms meeting the 2010 McDonald criteria for multiple sclerosis, and number of enhancing lesions at baseline together did not attenuate the betweengroup differences (Table S5 in the Supplementary Appendix). Similar results in favor of minocycline over placebo were obtained from the adjusted multiple-imputation analysis (Table S6 in the Supplementary Appendix) and the adjusted per-protocol analysis, which yielded absolute treatment differences of 17.3 percentage points (45.5% vs. 62.8%, P = 0.03) and 19.6 percentage points (43.5% vs. 63.1%, P = 0.02), respectively.
In a prespecified sensitivity analysis in which all the participants who withdrew early from the trial were considered to have treatment failure, the unadjusted risk difference was 19.9 percentage points (95% confidence interval [CI], 4.0 to 35.8) in favor of minocycline (P = 0.02). In a post hoc analysis, these differences remained significant at the 12-month time point but not at the secondary outcome time point of 24 months (Table 2 and Fig. 2 ). Because tests for interaction between treatment and specified subgroups were nonsignificant, there was no evidence for a differential minocycline effect within particular subgroups, except possibly in the comparison between the monofocal and multifocal subgroups (Fig. S1 in the Supplementary Appendix). A significant treatment-effect modification was observed for monofocal versus multifocal symptom onset (P = 0.02 for interaction), although the analysis was not adjusted for multiple comparisons. Within 6 months after randomization, 7 participants in the minocycline group and 14 participants in the placebo group met the trial outcome by having a relapse. Further details on clinical outcomes, and relapse outcomes and EDSS scores are provided in Tables S7, S9 , and S10 in the Supplementary Appendix. Although the relapse and EDSS outcomes numerically favored minocycline, none were statistically significant.
Secondary MRI Outcomes
Follow-up MRI was performed in 67 participants (93.1%) in the minocycline group and in 65 participants (92.9%) in the placebo group. The change in mean lesion volume on T 2 -weighted MRI, mean cumulative number of new enhancing lesions, and mean cumulative combined number of unique lesions all significantly favored minocycline over placebo at month 6 in the unadjusted and adjusted analyses ( Table 2) . By design, participants completed the trial when they reached the outcome of conversion to multiple sclerosis; therefore, fewer follow-up MRI scans were obtained in the placebo group (96 and 133 MRI scans over 6 months and 24 months, respectively) than in the minocycline group (109 and 169 MRI scans over 6 months and 24 months, respectively), because the participants who received placebo reached the outcome of conversion to multiple sclerosis sooner. At month 24, the unadjusted, but not the adjusted, MRI results showed significant differences between the minocycline group and the placebo group (Table 2) .
Adverse Events
More participants in the minocycline group than in the placebo group had adverse events (86.1% vs. 61.4%, P = 0.001), including rash (15.3% vs. 2.9%, P = 0.01), dental discoloration (8.3% vs. 0%, P = 0.01), and dizziness (13.9% vs. 1.4%, P = 0.005) ( Table 3, and Table S8 in the Supplementary Appendix). Four participants (two in the minocycline group and two in the placebo group) had transient grade 3 or 4 adverse events detected on laboratory testing, and four participants (one in the minocycline group and three in the placebo group) had five serious adverse events (Table 3) .
Discussion
The results of this trial suggest that 100 mg of minocycline, administered orally twice daily, may delay the conversion of the clinically isolated syndrome to multiple sclerosis, as defined according to the 2005 McDonald criteria. The adjusted risk difference of 18.5 percentage points at 6 months is similar to that with other disease-modifying therapies for multiple sclerosis. For example, Kaplan-Meier estimates of the rates of reduction in conversion from clinically isolated syndrome to multiple sclerosis at 6 months are approximately † Risk estimates, differences, and P values were calculated from actuarial life-table analyses (P = 0.001 and P = 0.007 by log-rank test for comparison of study groups over 6 months and 24 months of follow-up, respectively). ‡ Risk estimates, differences, and P values were calculated from actuarial life-table analyses, stratified according to number of lesions enhanced on MRI at baseline (P = 0.02 and P = 0.049 by stratified log-rank for comparison of study groups over 6 months and 24 months of follow-up, respectively). 26 percentage points with interferon beta-1a, 21 18 percentage points with teriflunomide, 22 and 25 percentage points with oral cladribine 23 ; however, direct comparisons with these agents were not performed in our trial. The presence of more than one enhancing lesion at baseline was a confounding factor in our analysis, but significant differences between the minocycline and placebo groups were maintained after adjustment for this finding. The effect of minocycline on MRI outcomes in this trial was similar to that in previous small trials in relapsing-remitting multiple sclerosis. 7, 8 This trial was shorter and smaller than other trials of therapies for a clinically isolated syndrome (Tables S11, S12, and S13 in the Supplementary Appendix). At 6 months, 61.0% of the participants in the placebo group in this trial reached the outcome of conversion to multiple sclerosis on the basis of the 2005 McDonald criteria, as compared with rates of 60 to 70% in placebo groups in other trials of therapies for clinically isolated syndrome. [20] [21] [22] [23] At the time this trial began, there was general acceptance of the 2005 McDonald criteria, which allowed a diagnosis of multiple sclerosis to be made before a second clinical relapse if new lesions were observed on follow-up MRI; therefore, it had become unethical to ask trial participants to continue receiving placebo after reaching the outcome of conversion to multiple sclerosis. 24 For this reason, participation in this trial was planned to be completed at 24 months or when participants reached the outcome of conversion to multiple sclerosis. During the trial period (November 2008 through December 2014), the 2010 McDonald criteria for multiple sclerosis became generally accepted, which would have reclassified some of the participants in this trial as having multiple sclerosis at the initial presentation. In the current trial, however, the treatment effect of minocycline was preserved in participants who retrospectively met the 2010 criteria (Fig. S1 in the Supplementary Appendix).
The small sample size was a limitation of our trial. It may have explained the imbalance in the proportion of participants who had symptom onset in the spinal cord and who had more than one enhancing lesion at baseline. However, the effect of minocycline in delaying conversion from a clinically isolated syndrome to multiple sclerosis remained significant after adjustment for the number of enhancing lesions at baseline and for symptom onset in the spinal cord. Sensitivity analyses yielded similar estimates of treatment effect. The small sample size, the inability to enroll the planned 154 participants, and the censoring of data for 32 participants (22.5%) limited the power at 24 months. Although adverse events and withdrawals from the trial were more frequent among the participants in the minocycline group than in the placebo group, the participants in the placebo group were more likely to reach the outcome of conversion to multiple sclerosis and thus had fewer MRI scans over time. The lack of MRI scans for 36.6% of the participants after month 3 could have introduced bias to the analysis of MRI outcomes.
In conclusion, this trial showed that the risk of conversion from a clinically isolated syndrome to multiple sclerosis at 6 months was significantly lower with minocycline than with placebo in both the unadjusted and adjusted analyses. This trial met a prespecified outcome of an absolute difference of 25 percentage points in the risk of conversion to multiple sclerosis in the unadjust- Placebo Minocycline ed analysis, and although the risk difference was smaller after adjustment for baseline imbalances, the differences remained significant and all MRI outcomes at 6 months favored minocycline over placebo. The between-group differences in outcomes were not sustained at 24 months. These results require confirmation in additional trials.
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